Analysts Set Verastem, Inc. (NASDAQ:VSTM) PT at $13.29

Shares of Verastem, Inc. (NASDAQ:VSTM) have received a consensus rating of “Moderate Buy” from the ten research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $13.2857.

Several analysts have recently weighed in on the stock. BTIG Research restated a “buy” rating and set a $20.00 price objective on shares of Verastem in a research report on Tuesday, September 9th. Zacks Research upgraded shares of Verastem to a “hold” rating in a research report on Tuesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Verastem in a research report on Wednesday. B. Riley raised shares of Verastem to a “strong-buy” rating in a report on Monday, August 25th. Finally, Wall Street Zen raised shares of Verastem from a “sell” rating to a “hold” rating in a report on Sunday, September 21st.

Verastem Stock Down 7.3%

VSTM opened at $8.57 on Monday. The company has a 50 day moving average of $8.71 and a 200 day moving average of $6.92. The company has a market cap of $527.40 million, a PE ratio of -2.61 and a beta of 0.89. Verastem has a 12 month low of $2.54 and a 12 month high of $11.24. The company has a current ratio of 3.46, a quick ratio of 3.44 and a debt-to-equity ratio of 2.06.

Verastem (NASDAQ:VSTM) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.25. The firm had revenue of $2.14 million during the quarter, compared to analysts’ expectations of $6.01 million. On average, sell-side analysts expect that Verastem will post -3.02 EPS for the current year.

Hedge Funds Weigh In On Verastem

Several institutional investors and hedge funds have recently made changes to their positions in VSTM. E Fund Management Co. Ltd. bought a new position in shares of Verastem during the 2nd quarter valued at $49,000. Nebula Research & Development LLC bought a new stake in shares of Verastem during the 2nd quarter valued at about $53,000. The Manufacturers Life Insurance Company boosted its stake in shares of Verastem by 9.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,188 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 1,440 shares in the last quarter. Profund Advisors LLC bought a new stake in shares of Verastem during the 2nd quarter valued at about $90,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Verastem during the 4th quarter valued at about $92,000. Institutional investors own 88.37% of the company’s stock.

Verastem Company Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.